Abstract Multiple factors regulate glucagon-like peptide-1 (GLP-1) secretion, but a group of apparently healthy subjects showed blunted responses of GLP-1 secretion in our previous study. In this study, we examined whether the reduction in GLP-1 secretory capacity is associated with increased extent of coronary artery stenosis in non-diabetic patients. Non-diabetic patients who were admitted for coronary angiography without a history of coronary interventions were enrolled. Coronary artery stenosis was quantified by Gensini score (GS), and GS ≥ 10 was used as an outcome variable based on its predictive value for cardiovascular events. The patients (mean age, 66.5 ± 8.8 years; 71% males, n = 173) underwent oral 75 g-glucose tolerant tests fo...
Abstract: Background: Incretin therapies appear to provide cardioprotection and improve cardiovascul...
BACKGROUND: Incretin therapies appear to provide cardioprotection and improve cardiovascular outcome...
The incretin glucagon-like peptide-1 (GLP-1) abolishes post-ischemic left ventricular contractility ...
Background: GLP-1 is an incretine hormone which gets secreted from intestinal L-cells in response to...
AIMS: Roles of glucagon-like peptide-1 (GLP-1) in extra-pancreatic tissues remain unclear. The aim o...
Aims: Roles of glucagon-like peptide-1 (GLP-1) in extra-pancreatic tissues remain unclear. The aim o...
Glucagon-like peptide-1 (GLP-1) may provide beneficial cardiovascular effects, possibly due to enhan...
Aims Glucagon-like peptide 1 (GLP-1) is a gut incretin hormone inducing post-prandial insulin secret...
Background. Glucagon-like peptide 1 (GLP-1) bestows protective effects upon the cardiovascular syste...
OBJECTIVE: While existing evidence supports beneficial cardiovascular effects of glucagon-like pepti...
Abstract Background Diabetes is a risk factor for peripheral, coronary, and cerebrovascular disease....
<div><p>Background and Aims</p><p>Glucagon-like peptide-1 (GLP-1) may provide beneficial cardiovascu...
AIMS/HYPOTHESIS: Recent studies have demonstrated that residual beta cells may be present in some pe...
One major risk factor of type 2 diabetes is the impairment of glucose-induced insulin secretion whic...
Aims/hypothesis Evidence that glucose-dependent insulinotropic peptide (GIP) and/or the GIP receptor...
Abstract: Background: Incretin therapies appear to provide cardioprotection and improve cardiovascul...
BACKGROUND: Incretin therapies appear to provide cardioprotection and improve cardiovascular outcome...
The incretin glucagon-like peptide-1 (GLP-1) abolishes post-ischemic left ventricular contractility ...
Background: GLP-1 is an incretine hormone which gets secreted from intestinal L-cells in response to...
AIMS: Roles of glucagon-like peptide-1 (GLP-1) in extra-pancreatic tissues remain unclear. The aim o...
Aims: Roles of glucagon-like peptide-1 (GLP-1) in extra-pancreatic tissues remain unclear. The aim o...
Glucagon-like peptide-1 (GLP-1) may provide beneficial cardiovascular effects, possibly due to enhan...
Aims Glucagon-like peptide 1 (GLP-1) is a gut incretin hormone inducing post-prandial insulin secret...
Background. Glucagon-like peptide 1 (GLP-1) bestows protective effects upon the cardiovascular syste...
OBJECTIVE: While existing evidence supports beneficial cardiovascular effects of glucagon-like pepti...
Abstract Background Diabetes is a risk factor for peripheral, coronary, and cerebrovascular disease....
<div><p>Background and Aims</p><p>Glucagon-like peptide-1 (GLP-1) may provide beneficial cardiovascu...
AIMS/HYPOTHESIS: Recent studies have demonstrated that residual beta cells may be present in some pe...
One major risk factor of type 2 diabetes is the impairment of glucose-induced insulin secretion whic...
Aims/hypothesis Evidence that glucose-dependent insulinotropic peptide (GIP) and/or the GIP receptor...
Abstract: Background: Incretin therapies appear to provide cardioprotection and improve cardiovascul...
BACKGROUND: Incretin therapies appear to provide cardioprotection and improve cardiovascular outcome...
The incretin glucagon-like peptide-1 (GLP-1) abolishes post-ischemic left ventricular contractility ...